Fluoropyrimidine-Associated Cardiotoxicity
| Autor: | Anuradha Godishala, Jaya Kanduri, Aarti Asnani, Luis Alberto More |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
medicine.medical_specialty
Antimetabolites Antineoplastic Myocarditis Heart Diseases Cardiomyopathy 030204 cardiovascular system & hematology Chest pain Global Health Sudden cardiac death 03 medical and health sciences 0302 clinical medicine Internal medicine Neoplasms Medicine Humans 030212 general & internal medicine Myocardial infarction Cardiotoxicity business.industry Cardiogenic shock Incidence General Medicine medicine.disease Coronary vasospasm cardiovascular system Cardiology Fluorouracil medicine.symptom Cardiology and Cardiovascular Medicine business |
| Zdroj: | Cardiology clinics. 37(4) |
| ISSN: | 1558-2264 |
| Popis: | Fluoropyrimidines are chemotherapeutic agents that confer great benefit to many patients with solid tumors, but their use is often limited by cardiotoxicity. The incidence and precise mechanisms of cardiotoxicity remain uncertain. Clinical presentations of fluoropyrimidine toxicity are varied and include chest pain, myocardial infarction, acute cardiomyopathy, arrhythmia, cardiogenic shock, and sudden cardiac death. Proposed mechanisms include coronary vasospasm, coronary endothelial dysfunction, direct myocardial toxicity, myocarditis, and Takotsubo cardiomyopathy. Therapeutic and prophylactic interventions primarily target coronary vasospasm as the underlying cause. Prospective studies are needed to develop evidence-based approaches to cardioprotection in patients receiving fluoropyrimidines. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|